Anti-CPI17 alpha antibody [E305]

• Supplier: Abcam
• Catalog: ab32213
• Prices: $381.00
• Sizes: 100 µl
• Host: Rabbit
• Clonality: Monoclonal
• Isotype: IgG
• Clone: E305
• Applications: WB IP
• Species Reactivities: Mouse, Rat, Human
• Antigen: Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human CPI17 alpha aa 1-100 (N terminal)
• Blocking Peptide: CPI17 alpha peptide
• Description: Rabbit Monoclonal
• Gene: PPP1R14A
• Conjugate: Unconjugated

Product images

Lanes 1, 2 & 4 : purified at 1/1000 dilutionLane 3 : RAW264.7 purified at 1/1000 dilutionLane 1 : C6 cell lysateLane 2 : PC-12 cell lysateLane 3 : cell lysateLane 4 : NIH/3T3 cell lysateLysates/proteins at 10 µg per lane.SecondaryHRP goat anti-rabbit (H+L) at 1/1000 dilution

Anti-CPI17 alpha antibody [E305] (ab32213) at 1/1000 dilution (purified) + Jurkat cell lysate at 10 µgSecondaryHRP goat anti-rabbit (H+L) at 1/1000 dilution

ab32213 (purified) at 1/50 immunoprecipitating CPI17 in MCF7 cell lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).Blocking buffer and concentration: 5% NFDM/TBST.Diluting buffer and concentration: 5% NFDM /TBST.

Anti-CPI17 alpha antibody [E305] (ab32213) at 1/1000 dilution (unpurified) + Jurkat cell lysate at 10 µgSecondaryHRP goat anti-rabbit (H+L) at 1/1000 dilution

All lanes : Anti-CPI17 alpha antibody [E305] (ab32213) at 1/5000 dilution (unpurified)Lane 1 : HeLa cell lysateLane 2 : Jurkat cell lysateLane 3 : MCF-7 cell lysateLane 4 : A431 cell lysate

ab32213 (unpurified) at 1/50 immunoprecipitating CPI17 in MCF7 cell lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).Blocking buffer and concentration: 5% NFDM/TBST.Diluting buffer and concentration: 5% NFDM /TBST.

Product References

Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin. - Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin.

Kang S, Woo HH, Kim K, Lim KM, Noh JY, Lee MY, Bae YM, Bae ON, Chung JH. Toxicol Sci. 2014 Apr;138(2):446-556.